Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | Avatrombopag following switch from eltrombopag or romiplostim in patients with ITP

Hanny Al-Samkari • 12 Jul 2022
ISTH 2022
Immune Thrombocytopenia Non-Malignant Avatrombopag Eltrombopag Romiplostim

Hanny Al-Samkari, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, outlines the results of a study investigating the responses of patients with immune thrombocytopenia (ITP) treated with avatrombopag following switch from eltrombopag or romiplostim. Overall, the study reported that patients treated with avatrombopag had a good durability of response. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

More from Hanny Al-Samkari

1:09
Emerging treatment options for refractory immune thrombocytopenia
Hanny Al-Samkari • 9 Dec 2023
1:25
Improving the sensitivity of platelet autoantibody testing for ITP diagnosis
Hanny Al-Samkari • 9 Dec 2023
1:31
Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency
Hanny Al-Samkari • 9 Dec 2023
1:46
Avatrombopag in patients with early versus chronic immune thrombocytopenia
Hanny Al-Samkari • 9 Dec 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals